Novo Nordisk creates AI division to help novel drug development

A new center in Seattle, US, will discover and develop new drugs using artificial intelligence. Recruitment for the new unit has begun.

Photo: Novo Nordisk / PR

The use of artificial intelligence (AI) is gaining popularity within the healthcare sector, where the technology is used to optimize hospital scheduling, indentify at-risk patients, support decision-making tools and more.

Novo Nordisk has now opened its eyes to the potential of AIs as a stepping stone in novel drug development – a potential so great that the Danish pharmaceutical giant is now establishing a center dedicated to this work.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs